Bausch & Lomb takes a haircut
If investors had hoped that the biggest medtech IPO for over a year could defy market sentiment, they were in for a disappointment. Bausch & Lomb, spun off from its parent Bausch Health, raised just $630m today – missing its target figure by more than $200m. Despite being profitable Bausch & Lomb was forced to price its shares $20% lower than its preannounced range. This is the latest chapter in the eye care company’s turbulent history: it is in fact returning to the New York exchange, having been listed there for half a century before being taken private by Warburg Pincus for $4.5bn in 2007. Warburg sold it to Valeant Pharmaceuticals six years later for $8.7bn. Valeant changed its name to Bausch Health in 2018 in an effort to shake off accusations of price-gouging and sharp accounting practices, and today owns 90% of Bausch & Lomb. Perhaps Bausch & Lomb is lucky to get away at all in such a volatile market – it is notable that the deal is only the third listing of a medtech company this year. Still, its current valuation of around $6.3bn means that the parent group has lost out in a major way.
|2022's medtech IPOs so far|
|Date||Company||Focus||Amount raised ($m)||Premium/
|Feb 16||Meihua International Medical Technologies||General & plastic surgery||36||0%||Nasdaq|
|Apr 27||Tenon Medical||Orthopaedics||16||0%||Nasdaq|
|May 6||Bausch & Lomb||Ophthalmology||630||-20%||NYSE|
|Source: Evaluate Medtech.|